Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01545778
Other study ID # CR100822
Secondary ID RRA-5950
Status Completed
Phase N/A
First received February 28, 2012
Last updated October 26, 2012
Start date February 2010
Est. completion date February 2012

Study information

Verified date October 2012
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact n/a
Is FDA regulated No
Health authority United States: None due to the nature of the study (Registry)
Study type Observational

Clinical Trial Summary

The purpose of this study is to compare the risk of shopping behavior of tapentadol immediate release with the risk of shopping behavior of oxycodone immediate release.


Description:

This is a retrospective (a study that looks backward in time, usually using medical records and interviews with patients) matched cohort (designated group followed or traced over a period of time) study using IMS LRx database. This database covers 65% of all retail prescriptions in the United States and includes mail service and specialty pharmacy provider prescriptions independent of the method of payment. The study will include Opioid naive patients exposed to tapentadol immediate release (IR) or oxycodone IR from July 2009 to December 2010. A naive patient is a patient who has not received an opioid of any type in the 3 months before the index date. The index date is the date of the first prescription for tapentadol IR or oxycodone IR after June 30, 2009. Patients will be followed for 1 year from their index dates. Each tapentadol IR-exposed patient will be matched to up to 4 oxycodone IR-exposed patients. Matching will allow to control in the design for potential confounding variables such as time of the exposure, geographic area, specialty of the prescriber, and age. These are variables that have been related with the risk of shopping behavior or abuse.


Recruitment information / eligibility

Status Completed
Enrollment 646620
Est. completion date February 2012
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Opioid naive patients (a patient who has not received an opioid of any type in the 3 months before the index date) exposed to tapentadol IR or oxycodone IR from July 2009 to December 2010 [The index date is the date of the first prescription for tapentadol IR or oxycodone IR after June 30, 2009]

Exclusion Criteria:

- Patients with use of any opioid 3 months before the index date

- Patients who within 4 days on or after the index date fill a prescription for a different opioid

- Patients who within 4 days on or after the index date fill a prescription for the same opioid but written by a different prescriber

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Related Conditions & MeSH terms


Intervention

Drug:
Tapentadol IR
Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
Oxycodone IR
Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients who developed shopping behavior defined as patients with prescriptions with at least one day of overlap, written by = 2 different prescribers and filled in 3 or more pharmacies 12 months No
Secondary Time to first episode of shopping behavior 12 months No
Secondary The number of shopping episodes during the year of follow up 12 months No
Secondary The type of dispensing in the first episode of shopping event The type of dispensing in the shopping event will be classified as "Only the indexed opioid" "Indexed opioid was involved", or "Indexed opioid was not involved at all". 12 months No
See also
  Status Clinical Trial Phase
Completed NCT01124591 - Brief Intervention for Drug Misuse in the Emergency Department Phase 2
Completed NCT01037569 - Optimizing Toxicological Screening in Drug Endangered Children N/A